Sept. 26 Preclinical Quick Takes: $30M for new lung disease lab; plus AI-derived compounds from Auransa, Atomwise, and diabetes candidates

Bayer, Brigham and Mass General open lung disease-focused lab
Bayer AG (Xetra:BAYN) will invest more than $30 million over five years to fund research into new treatments for chronic lung diseases, such as chronic obstructive pulmonary

Read the full 358 word article

How to gain access

Continue reading with a
two-week free trial.